Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New genetic test for DEPOH in sighthounds
DEPOH is an important health problem in certain sighthound breeds.

The test will allow vets to target the use of preventative medication.

Researchers at Washington State University, supported by the Scottish Deerhound Club of America, have developed a new genetic test that can identify dogs at risk of a condition known as delayed postoperative haemorrhage (DEPOH). The disorder can result in excessive bleeding and bruising in the hours and days after major surgery.

The test was developed following a study of 269 privately owned deerhounds. The dogs were evaluated with an objective of identifying genes associated with DEPOH.

The researchers used genome-wide association analysis to identify a single region on chromosome 9 that contained 40 candidate genes. Further screening of the candidate genes was performed and only the DEPOH gene was identified as being directly linked to the pathophysiology of the disorder.

DEPOH is a potentially fatal disorder that can vary in severity from minor bruising to life-threatening haemorrhaging. The condition typically occurs one to four days after major surgery when blood clots begin to break down too soon, in a process called hyperfibrinolysis.

First identified in racing greyhounds in 2007, DEPOH is an important health problem in certain sighthound breeds, including Scottish deerhounds and greyhounds. Following the identification of the DEPOH gene, the mutation has been discovered in additional sighthounds such as Italian greyhounds and salukis, as well as other breeds including golden retrievers and border collies.

Dogs with a mutation of the DEPOH gene are at higher risk than other dogs of developing the condition post surgery. The new test will allow veterinary surgeons to administer antifibrinolytic drugs to those that test positive for the gene before any surgery.

Previously, veterinary surgeons would have had to administer preventative medication indiscriminately, which can be costly and lead to adverse reactions.

Health and genetics commission chair for the Scottish Deerhound Club of America Dr. John Dillberger said: “Now pet owners can test their dog at any time in its life to understand whether it is at risk.

“And if it is, before planning any scheduled or elective surgery, they can make sure the surgeon is aware of it and prepare accordingly. This will help save the lives of pets.”

The study has been published by the Journal of Veterinary Medicine.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.